Literature DB >> 21963217

Nitric oxide generation affects pro- and anti-angiogenic growth factor expression in primary human trophoblast.

K A Groesch1, R J Torry, A C Wilber, R Abrams, A Bieniarz, L J Guilbert, D S Torry.   

Abstract

OBJECTIVES: Preeclampsia is associated with reduced trophoblast placenta growth factor (PGF) expression, elevated soluble fms-like tyrosine kinase-1 (sFlt-1) and decreased bioactivity of nitric oxide (NO). Elevated sFlt-1 reduces bio-availability of PGF and vascular endothelial growth factor (VEGF) leading to maternal endothelial dysfunction. Although NO can regulate gene expression, its ability to regulate trophoblast expression of angiogenic growth factors is not known. STUDY
DESIGN: Human primary term trophoblast and JEG-3 choriocarcinoma cells were cultured under 21%O(2) or 1%O(2) conditions in the presence or absence of NO donor (SNP) or inhibitor (L-NAME). Effects on PGF, VEGF and Flt-1 isoform mRNA expression were determined by quantitative real-time PCR. Changes in expression of soluble protein isoforms of FLT-1 was monitored by ELISA.
RESULTS: Hypoxia decreased PGF mRNA but increased VEGF, sFlt-1 and Flt-1 mRNA expression in trophoblast. Generation of NO in trophoblast under 1%O(2) culture conditions significantly reversed sFlt-1 mRNA and protein expression, independent of mFlt-1. Conversely NO generation in hypoxic trophoblast increased VEGF and PGF mRNA expression.
CONCLUSIONS: NO production in primary human trophoblast cultures had divergent effects on pro-angiogenic (PGF, VEGF) versus anti-angiogenic (sFlt-1) mRNA expression, resulting in an enhanced pro-angiogenic gene expression environment in vitro.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963217      PMCID: PMC3269960          DOI: 10.1016/j.placenta.2011.08.008

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  44 in total

1.  Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1.

Authors:  Ori Nevo; Nima Soleymanlou; Yuan Wu; Jing Xu; John Kingdom; Ariel Many; Stacy Zamudio; Isabella Caniggia
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-04-20       Impact factor: 3.619

2.  Nitric oxide-induced nuclear translocation of the metal responsive transcription factor, MTF-1 is mediated by zinc release from metallothionein.

Authors:  Molly S Stitt; K J Wasserloos; X Tang; X Liu; Bruce R Pitt; Claudette M St Croix
Journal:  Vascul Pharmacol       Date:  2006-01-19       Impact factor: 5.773

3.  Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta.

Authors:  H Li; B Gu; Y Zhang; D F Lewis; Y Wang
Journal:  Placenta       Date:  2005 Feb-Mar       Impact factor: 3.481

4.  Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro.

Authors:  B Xu; C Thornton; J Tooher; R Ogle; S Lim; A Makris; A Hennessy
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-02-10       Impact factor: 2.557

5.  Differential regulation of human PlGF gene expression in trophoblast and nontrophoblast cells by oxygen tension.

Authors:  R M Gobble; K A Groesch; M Chang; R J Torry; D S Torry
Journal:  Placenta       Date:  2009-08-26       Impact factor: 3.481

6.  Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice.

Authors:  Hirotada Suzuki; Akihide Ohkuchi; Shigeki Matsubara; Yuji Takei; Masato Murakami; Masabumi Shibuya; Mitsuaki Suzuki; Yasufumi Sato
Journal:  Hypertension       Date:  2009-09-28       Impact factor: 10.190

7.  Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats.

Authors:  Jason P Bridges; Jeffrey S Gilbert; Drew Colson; Sara A Gilbert; Matthew P Dukes; Michael J Ryan; Joey P Granger
Journal:  Am J Hypertens       Date:  2009-03-05       Impact factor: 2.689

Review 8.  The role of the L-arginine-nitric oxide pathway in preeclampsia.

Authors:  Patricio López-Jaramillo; William D Arenas; Ronald G García; Melvin Y Rincon; Marcos López
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-08

9.  Role of inflammatory cytokines and eNOS gene polymorphism in pathophysiology of pre-eclampsia.

Authors:  Archana Singh; Deepika Sharma; Chitra Raghunandan; Jayashree Bhattacharjee
Journal:  Am J Reprod Immunol       Date:  2009-12-29       Impact factor: 3.886

10.  Metal transcription factor-1 is involved in hypoxia-dependent regulation of placenta growth factor in trophoblast-derived cells.

Authors:  Fumihito Nishimoto; Masahiro Sakata; Ryoko Minekawa; Yoko Okamoto; Asako Miyake; Aki Isobe; Toshiya Yamamoto; Takashi Takeda; Emi Ishida; Kenjiro Sawada; Ken-Ichiro Morishige; Tadashi Kimura
Journal:  Endocrinology       Date:  2008-11-20       Impact factor: 4.736

View more
  10 in total

Review 1.  Perspective: L-arginine and L-citrulline Supplementation in Pregnancy: A Potential Strategy to Improve Birth Outcomes in Low-Resource Settings.

Authors:  Andrea M Weckman; Chloe R McDonald; Jo-Anna B Baxter; Wafaie W Fawzi; Andrea L Conroy; Kevin C Kain
Journal:  Adv Nutr       Date:  2019-09-01       Impact factor: 8.701

2.  Maternal perfluorooctane sulfonic acid exposure during rat pregnancy causes hypersensitivity to angiotensin II and attenuation of endothelium-dependent vasodilation in the uterine arteries †.

Authors:  Sri Vidya Dangudubiyyam; Jay S Mishra; Ruolin Song; Sathish Kumar
Journal:  Biol Reprod       Date:  2022-10-11       Impact factor: 4.161

3.  Inflammation in Preeclampsia: Genetic Biomarkers, Mechanisms, and Therapeutic Strategies.

Authors:  Yue Wang; Baoxuan Li; Yan Zhao
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 4.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

5.  Testosterone alters maternal vascular adaptations: role of the endothelial NO system.

Authors:  Vijayakumar Chinnathambi; Meena Balakrishnan; Jayanth Ramadoss; Chandrasekhar Yallampalli; Kunju Sathishkumar
Journal:  Hypertension       Date:  2013-01-21       Impact factor: 10.190

6.  The role and mechanism of asymmetric dimethylarginine in fetal growth restriction via interference with endothelial function and angiogenesis.

Authors:  Yan Dai; Jun Zhang; Rong Liu; Na Xu; Song-Biao Yan; Yi Chen; Tian-He Li
Journal:  J Assist Reprod Genet       Date:  2020-03-25       Impact factor: 3.412

7.  Sildenafil Inhibits Advanced Glycation End Products-induced sFlt-1 Release Through Upregulation of Heme Oxygenase-1.

Authors:  Jae Hyeok Jeong; Hwi Gon Kim; Ook Hwan Choi
Journal:  J Menopausal Med       Date:  2014-08-27

8.  Malaria in pregnancy alters l-arginine bioavailability and placental vascular development.

Authors:  Chloe R McDonald; Lindsay S Cahill; Joel L Gamble; Robyn Elphinstone; Lisa M Gazdzinski; Kathleen J Y Zhong; Adrienne C Philson; Mwayiwawo Madanitsa; Linda Kalilani-Phiri; Victor Mwapasa; Feiko O Ter Kuile; John G Sled; Andrea L Conroy; Kevin C Kain
Journal:  Sci Transl Med       Date:  2018-03-07       Impact factor: 17.956

Review 9.  The Role of Nitric Oxide, ADMA, and Homocysteine in The Etiopathogenesis of Preeclampsia-Review.

Authors:  Weronika Dymara-Konopka; Marzena Laskowska
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

10.  Red Light Mitigates the Deteriorating Placental Extracellular Matrix in Late Onset of Preeclampsia and Improves the Trophoblast Behavior.

Authors:  Jakara Griffin; John G Krolikowski; Kenisha Kounga; Janine Struve; Agnes Keszler; Brian Lindemer; Michelle Bordas; Grant Broeckel; Nicole L Lohr; Dorothee Weihrauch
Journal:  J Pregnancy       Date:  2022-04-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.